Drug intelligence / Profile preview

prosaptide

Development stage
Discontinued
Lead developer
Amgen
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Subcutaneous
01

Overview

Prosaptide is a synthetic peptide derived from the neurotrophic region of the multifunctional protein prosaposin. It is a recombinant polypeptide with neuroprotective and glioprotective properties, acting as an agonist at G protein-coupled receptors GPR37 and GPR37L1. Prosaptide has been shown to stimulate neuronal survival pathways, prevent hyperalgesia, reduce peripheral neuropathy, and activate anti-apoptotic mechanisms in preclinical models. It was primarily developed for the treatment of neuropathic pain associated with diabetic neuropathy and HIV-associated sensory neuropathies but did not demonstrate efficacy in phase 2 clinical trials. The drug also showed potential protective effects against ischemia-induced hearing loss and was investigated for its ability to inhibit tumor metastasis via stimulation of p53 and thrombospondin-1 (TSP-1) pathways in cancer models[1][4][5][6][8][9].

Other names
prosaposin-derived peptidePS-pep
02

Targets

GPR37 (G protein-coupled receptor 37)GPR37L1 (G protein-coupled receptor 37-like 1)

Beyond the preview

Go deeper on prosaptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prosaptide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call